Kato, K., Doi, T., Adenis, A., Shah, M. A., Enzinger, P. C., Shen, L., Ishida, T. C., Suttner, L., Sharan, K., Bhagia, P., Sun, J. (2025). KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4209